Merck and Eisai's Keytruda (pembrolizumab) + Lenvima (lenvatinib) Receive the US FDA's Approval for the Treatment of Advanced Endometrial Carcinoma
Shots:
- The approval is based on P-III KEYNOTE-775/Study 309 trial evaluating Merck’s Keytruda (200mg- IV- q3w) + Eisai’s Lenvima (20mg- PO- qd) vs CT (doxorubicin- 60 mg/m2- IV- q3wks.) or paclitaxel (80 mg/m2- IV- 28-day cycle) in 827 patients with advanced EC that were not MSI-H or dMMR- prior treated with Pt-based regimen in any setting
- Results: improvements in OS (32% reduction in risk of death)- 40% reduction in risk of disease progression or death- ORR (30% vs 15%) - CR rate (5% vs 3%) - PR rate (25% vs 13%)- mDoR (6.8 vs 6.7mos.)
- Keytruda + Lenvima was previously approved under the FDA’s accelerated approval process as well as RTOR program & Project Orbis for EC
Ref: Businesswire | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com